Systemic therapy outperforms intraocular implant for treating uveitis

Systemic therapy consisting of corticosteroids and immunosuppressants preserved vision of uveitis patients better – and had fewer adverse outcomes – than a long-lasting corticosteroid intraocular implant, according to a clinical trial funded by the National Eye Institute (NEI). After seven years, visual acuity on average remained stable among participants on systemic therapy but declined by an average of si x letters (about one line on an eye chart) among participants who had the implant. NEI is part of the National Institutes of Health.
Source: News from NEI - Category: Opthalmology Authors: Source Type: news